Skip to content

Effect of Adding Aripiprazole as Adjunctive Therapy for Obsessive-Compulsive Symptoms in Patients with Bipolar I Disorder

· 0 citations · 16 references

TL;DR

Preliminary findings suggest that an 8-week course of adjunctive aripiprazole is well tolerated and may reduce comorbid obsessive-compulsive symptoms in patients with BP-I, with improvement persisting through a 4-week off-treatment follow-up.

View source

Similar papers

Open access Sep 2026

Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder with Comorbid Treatment-Resistant Depression: A Six-Month Case Report

Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–c...

T. Barlattani, Giorgio Sernia, C. D'Amelio et al. · 0 citations
Sep 2026

Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder: A Prospective Naturalistic Study.

BACKGROUND Borderline personality disorder (BLPD) is a complex and debilitating psychiatric condition with high prevalence and clinical and psychosocial burden. Psychotherapy is the recommended first-line treatment but, in real-world clinical practice, most individuals with BLPD are prescribed psychotropic medications,...

M. D'Incalci, C. M. Congedo, G. Agostoni et al. · 0 citations
Open access Oct 2026

Esketamine’s therapeutic effect on anhedonia in adolescents: a post-hoc of a randomized controlled trial

Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored. In this study, a prosp...

Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al. · 0 citations
Review Open access Sep 2026

Antipsychotic-associated obsessive–compulsive symptoms and disorder: scoping review of mechanisms, comparative epidemiology and clinical implications

Background Antipsychotic agents play a paradoxical role in obsessive–compulsive phenomena, augmenting selective serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder yet also inducing or worsening obsessive–compulsive symptoms, mainly in psychotic but also in mood disorders. How strongly in...

Muhanad Elnoor, Syed Ali Bokhari, S. Javaid · 0 citations
Clinical trial Sep 2026

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.

It is suggested that psilocybin therapy may be safe, tolerable, and preliminarily efficacious for treating depression in BD-II, but randomized controlled trials are needed to confirm efficacy and optimize protocols.

Amanda E. Downey, B. Szigeti, Ellen R. Bradley et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.